Zhang et al.’s analysis of 10,195 solid tumor patients showed that MUC16 mutations correlate with a higher tumor mutational burden (TMB) and neoantigen load, increased CD8A and PD-L1 expression in the tumor immune microenvironment, and are linked to improved patient survival and clinical response rates, highlighting their significance as genomic markers in evaluating response to immune checkpoint inhibitors (ICIs) therapy (78). Here, MUC16 is linked to neoplasm.